When we were designing Daily Cognitive, the single most contested number on the label was the citicoline dose. The case for 500mg was strong. The case for 1g was tempting. Here's how we decided.

Citicoline — also known as CDP-choline — is the gold-standard nootropic ingredient for one reason: it's the only cognitive supplement with multiple high-quality randomized controlled trials in healthy adults. Not in patients with cognitive decline. Not in elderly populations. Healthy, working-age adults. Trials measuring attention, processing speed, and working memory.

The most-cited of these trials is Silveri et al., 2008, published in NMR in Biomedicine. The protocol: 50 healthy adults, randomized to citicoline or placebo, dosed at 500mg per day, measured over 28 days. The result: measurable improvements in attention and psychomotor speed in the citicoline group, with effects emerging at week 4.

500mg is the dose. That's the bar. So why did we even consider doubling it?

The case for more.

The argument for a higher dose isn't unreasonable. Several pharmacological studies have used citicoline at 1g, 2g, even 4g per day, particularly in clinical contexts like stroke recovery and ischemic injury. The molecule has an exceptional safety profile — no significant adverse events at doses up to several grams. And in supplement marketing, more is generally read as better. A label that says "1,000mg citicoline" sells more bottles than one that says "500mg," all else equal.

So if it's safe at higher doses, and the marketing favors bigger numbers, why not push it?

The answer is in the dose-response data. When you look at the trials that compared multiple doses head-to-head — particularly Spiers et al., 1996 and the follow-up work in Bulletin of the Society of Pharmacology and Experimental Therapeutics — a clear pattern emerges. The cognitive performance benefits in healthy adults plateau around 500mg. Going to 1g doesn't double the effect. In some measures, it doesn't improve the effect at all.

The higher doses do something — but what they do is different. Higher doses extend the clinical applications: stroke rehabilitation, ischemic recovery, severe attentional disorders. Those are different conditions, different outcomes. If your goal is improving cognitive performance in a healthy adult, the data says 500mg is the dose.

The cost-per-serving math.

Now we get to the part of the conversation that most supplement brands won't have publicly. Citicoline is expensive. Pharmaceutical-grade CDP-choline at the verified-identity level we use costs roughly $0.85 per 500mg serving at our scale. Doubling the dose doesn't double the cost — bulk purchasing helps — but it adds roughly $0.55 per serving, or about $16 per 30-day bottle.

If that $16 produced meaningfully better outcomes for the customer, it would be a no-brainer — you charge an extra $20 retail, you absorb the small margin hit, you launch the better product. But the data says it doesn't. Doubling the dose adds $16 of cost without adding clinical effect. And the customer pays for that cost twice: once in dollars, and once in the form of larger capsules or more pills per day.

The "more is better" trap.

This is where the supplement industry's default logic breaks down. The honest answer is that for citicoline specifically, in healthy adult cognition specifically, more isn't better. It's just more. We could put 1g on the label, charge another $20, and most customers would assume they were getting a superior product. They wouldn't be. They'd be paying for headroom that doesn't translate to outcomes.

The decision to dose at 500mg — the dose the studies used, the dose that delivers the effect, no more — is the brand thesis in miniature. Match the studies. Don't pad the label. Don't pretend bigger numbers are better numbers when the data says otherwise.

Figure: dose-response visualization based on aggregated trial data, 1996-2012.

What this means for the formulation.

The 500mg citicoline decision then constrained everything else. Once we knew the dose, we knew the cost per serving. Once we knew the cost per serving, we knew the price ceiling. Once we knew the price ceiling, we could figure out how much of the budget was available for the other six ingredients — and what trade-offs we'd need to make on form, supplier, and standardization for each.

This is how formulation actually works. It's not "what ingredients are trending." It's: here's the strongest evidence-backed ingredient, here's the dose the evidence supports, here's what that costs us, and what does the rest of the formula look like inside that constraint?

If we'd chosen 1g, the rest of the formulation would have had to come down to compensate. Less Lion's Mane. Cheaper Bacopa extract. Generic L-theanine instead of Suntheanine. A bigger headline number on one ingredient at the cost of six others. That's not a better product. That's a louder label.

The takeaway.

The interesting thing about clinical-dose formulation is that it forces you to confront which decisions are actually about the customer's outcome and which are about the customer's perception. 1g of citicoline would have looked better on the label. 500mg works better in the body. Those aren't always the same number.

Every ingredient in Daily Cognitive has a version of this story. The Bacopa dose is 320mg because that's the standardized bacoside content used in the 12-week trials, not because we wanted to hit a round number. The Lion's Mane is 1g of verified fruiting body extract because that's what the Mori trial used, not 500mg of mycelium-on-grain. The L-Theanine is the branded Suntheanine form, not the cheaper generic, because Suntheanine is the form the clinical data is based on.

The label is a long list of decisions like these. The Journal is where we explain them.

— K.